Target intelligence / Profile preview

Gamma-delta T-cell receptor (γδ T-cell receptor) (γδ TCR)

Target
γδ TCR
Molecular classification
Receptor, T-cell receptor (non-classical), Cell surface protein complex
01

Overview

The **γδ T-cell receptor (γδ TCR)** is a heterodimeric cell-surface receptor expressed predominantly on γδ T cells, a distinct subset of T lymphocytes. Unlike classical αβ T-cell receptors, the γδ TCR recognizes a range of antigens without presentation by traditional major histocompatibility complex (MHC), including small phosphorylated molecules known as phosphoantigens (PAgs), as well as stress-induced protein ligands. Most notably, the human Vγ9Vδ2 subset reacts to phosphoantigens produced by both microbial pathogens and dysregulated tumor cell metabolism, requiring the presence of accessory proteins butyrophilin 3A1 (BTN3A1) and butyrophilin 2A1 (BTN2A1) for activation. Engagement of phosphoantigens by BTN3A1 (plus BTN2A1) alters their conformation and enables interaction with the γδ TCR, leading to rapid T-cell activation, cytokine release, and direct killing of target cells. This pathway has made γδ TCR an attractive target for cancer and infectious disease immunotherapy, but clinical translation has been limited by imperfect efficacy, complex activation requirements, and immune regulatory effects, including possible self-limiting responses and suppression of natural killer cell function.

Other names
Vγ9Vδ2 T-cell receptorGamma-delta TCRTCRγδGamma-delta T cell antigen receptor
02

Mechanism of action

Activation of γδ T cells via recognition of phosphoantigens presented on cell surfaces with involvement of butyrophilin proteins, leading to cytokine release and cytotoxic response

03

Biological functions

Immune responseAntigen recognitionTumor cell killingRegulation of innate and adaptive immunitySignal transduction
04

Disease associations

CancerInfectionInflammationOther immune diseases
05

Safety considerations

Limited clinical efficacy in trials (γδ T cell-based immunotherapy)Potential autoimmunity or off-target effectsγδ T cell exhaustion and self-killing (apoptosis) upon self-activation, which may limit therapy efficacySuppression of natural killer cell responses in certain contexts
06

Interacting drugs

Zoledronic acid (through upregulation of endogenous phosphoantigens)

2 more in the full profile.

07

Biomarkers

Vγ9Vδ2 TCR expression (for patient selection in γδ T cell-based immunotherapy)BTN3A1 or BTN2A1 expression (cofactors necessary for phosphoantigen-mediated activation)

Beyond the preview

Go deeper on Gamma-delta T-cell receptor (γδ T-cell receptor) (γδ TCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-delta T-cell receptor (γδ T-cell receptor) (γδ TCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call